Sign Up

Home of Hepatology7 rue Daubin1203 GenevaSwitzerland+41 22 807 03 60easloffice@easloffice.eu© 2025 EASL. All rights reserved.Website by Soto.Privacy Policy | Cookie Policy | Terms & Conditions | Cyber Security Explore offerUnlock the full potential of being part of the EASLcommunity. As a member, you’ll gain access toexclusive resources, reduced event fees, top-tierjournals, and professional development opportunitiesdesigned to support your career in hepatologyBecome a memberNurses & Allied Health ProfessionalsLink titleYoung InvestigatorsLink titleBasic ScienceLink titleTitle here Lorem ipsum At the heart of EASL is a diverse and dynamic international community of professionals dedicated to advancing hepatology.Discover how you can get involved and make an impact.Whether you're a member, a Young Investigator, a nurse or allied health professional, or focused on basic science, there's a place for you here. Explore the different pathways to connect, grow and contribute, from membership benefits to tailored programmes and scientific networksLorem ipsum dolor sit ipsum CommunitySign In / Sign UpResourcesWhat We DoAbout Us Partnerships
Flyout Menu
Main Menu

Resmetirom and Semaglutide in MASH: Who, when and how to monitor?

Key Information

Location: Talk Liver To Me podcast
Dates: 23 September, 2026
  • Topic: Metabolism, Alcohol & Toxicity
Register now
Visit Website
Access Programme
Submit Abstract
Add to Calendar

This episode of Talk Liver to Me explores the practical use of resmetirom and semaglutide in MASH, based on the 2026 EASL–EASD–EASO Guidance. Experts discuss who may benefit from treatment, when to initiate therapy, and how to monitor response and efficacy in clinical practice.

Host: Debbie Shawcross (EASL)
Guests: Andrea Ciudin (EASO), Amelia Gastaldelli (EASD) Frank Tacke (EASL)

Talk Liver To Me is supported by Boehringer Ingelheim, GSK, IPSEN and Opella. Sponsors have had no input to the content of this programme.

Scroll to Top

Search EASL